Clinical Trial Update: A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment [Phase 1]

View source ↗

Summary

Phase 1 single-dose study to assess pharmacokinetics of LY2189265 in subjects with varying degrees of hepatic impairment, including those with Type 2 diabetes m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• LY2189265

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED | Results posted: 2014-10-07